Biomarkers that predict response to ICI therapy (e.g. presence of tumor infiltrating lymphocytes, PD-L1 expression, tumor mutational burden, MMR deficiency) are determined by immunohistochemistry (IHC) or genetic methods and require tumor tissue. Here, CD274 is linked to neoplasm.